News

Natural Selection in Antibody R&D: Survival of the Fittest

Date and time: Thu, Dec 7, 2023 11:30 AM - 12:30 PM CET Location: Dinaqor - Conference Room, Wagistrasse 25, 8952 Schlieren Rapid Novor is at the forefront of accelerating therapeutic antibody discovery with our cutting-edge REpAb® platform. Based in Canada, our expertise lies in de novo protein sequencing, advancing the capabilities...

read more

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present additional positive data from its Phase 1 study of MP0317 in patients with advanced...

read more